Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.

Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience / Francini E; Fiaschi Ai; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G.. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - STAMPA. - 26:(2015), pp. 884-887. [10.1097/CAD0000000000000257]

Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience

Francini E;Laera L;Ponchietti R;Roviello G.
2015

Abstract

Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
2015
26
884
887
Goal 3: Good health and well-being for people
Francini E; Fiaschi Ai; Petrioli R; Laera L; Bianco V; Ponchietti R; Roviello G.
1a - Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Tolerability-of-cabazitaxel-2015.pdf

Accesso chiuso

Dimensione 101.23 kB
Formato Adobe PDF
  Richiedi una copia
101.23 kB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1156870
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact